Pharma BD Deal Intelligence
Allergan's $3.2B Inamed buy delivered a durable aesthetics win in Natrelle breast implants but a bust on the other half: the Lap-Band obesity device business was sold off in 2013 for as little as $75M cash, and the implant platform later triggered a 2019 worldwide recall over BIA-ALCL cancer risk.
The breast-implant half (Natrelle) became a durable aesthetics franchise; the obesity-device half (Lap-Band), roughly a third of the deal's value driver, was sold off eight years later for pennies on the dollar and later entangled Allergan in a cancer-recall and False Claims Act scandal.
Full analysis, sources & comparables →Allergan's bid valued Inamed at roughly $3.2-3.5B, beating an earlier Medicis offer that had been challenged on antitrust grounds for combining the leading…
FTC required Allergan to divest Reloxin US rights back to Ipsen as a condition of the $3.2B Inamed acquisition, citing risk that the deal would eliminate the…
Allergan and Inamed cleared the final antitrust hurdle by handing Reloxin rights back to Ipsen, allowing the $3.2B aesthetics combination to close in March…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Allergan announces $3.2B acquisition of Inamed ($84/share cash or 0.8498 shares); medical aesthetics/breast implants. FTC required Reloxin divestiture. Closed March 2006.
The breast-implant half (Natrelle) became a durable aesthetics franchise; the obesity-device half (Lap-Band), roughly a third of the deal's value driver, was sold off eight years later for pennies on the dollar and later entangled Allergan in a cancer-recall and False Claims Act scandal.
Assessment window: 15yr post-close.
Medical aesthetics covers cash-pay procedures and devices used in cosmetic enhancement and reconstruction, including silicone/saline breast implants, hyaluronic acid dermal fillers, and adjustable gastric banding for obesity. Demand is highly elastic to consumer income and provider promotion, and reimbursement is generally out-of-pocket.
Pre-deal, the US botulinum toxin and dermal filler market was anchored by Allergan's Botox Cosmetic, with Medicis (Restylane/Perlane) the dominant filler; Mentor and Inamed were the two FDA-cleared silicone breast implant suppliers; Medicis and Galderma led HA fillers in the US. Inamed brought Juvederm (HA filler licensed from Corneal/LEA Derm), McGhan/Natrelle silicone and saline implants, the LAP-BAND adjustable gastric banding system, and the Reloxin/Dysport (abobotulinumtoxinA) US development program licensed from Ipsen. The FTC required Allergan to return Reloxin US rights to Ipsen on the theory that Reloxin was the most likely near-term competitor to Botox. The deal converted Allergan from a Botox-and-eyecare company into the integrated leader in medical aesthetics, with paired toxin + filler + implant offerings and a sales force calling on plastic surgeons and dermatologists - the architecture that defined the category for the next 15 years.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Allergan plc / Inamed Corporation (this deal) | 2005 | $3.2B | 50 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
| Allergan plc / SkinMedica, Inc. | 2012 | $375M | 55 |
| Allergan plc / Oculeve, Inc. | 2015 | $250M | 33 |
| Allergan plc / Zeltiq Aesthetics, Inc. | 2017 | $2.5B | 32 |
| Allergan plc / Kythera Biopharmaceuticals, Inc. | 2015 | $2.1B | 23 |
| Allergan plc / Anterios, Inc. | 2016 | $90M | 19 |
← Browse all deals · How we score deals
More: 2005 deals · Allergan plc deals